<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00667576</url>
  </required_header>
  <id_info>
    <org_study_id>M10-309</org_study_id>
    <nct_id>NCT00667576</nct_id>
  </id_info>
  <brief_title>Dose-response Study of Paricalcitol Injection in Chronic Kidney Disease Patients Receiving Hemodialysis</brief_title>
  <official_title>Late Phase 2 Study of Paricalcitol Injection: Dose-response Study of Paricalcitol Injection in Chronic Kidney Disease Subjects Receiving Hemodialysis With Secondary Hyperparathyroidism (Examination of Initial Dose and Incremental Dose)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Abbott Japan Co.,Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Abbott</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to investigate the initial dose and dose adjustment range for
      paricalcitol injection in patients with chronic kidney disease on hemodialysis who have
      secondary hyperparathyroidism.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This multicenter, randomized, open-label trial consisted of 4 dose-adjustment regimens for
      paricalcitol injection (initial doses and dose adjustment ranges were 2 ± 1 µg, 2 ± 2 µg, 4 ±
      1 µg, and 4 ± 2 µg) and 1 maxacalcitol regimen (initial dose and dose adjustment range was 5
      µg ± 2.5 µg or 10 µg ± 2.5 µg) as a reference group. Subjects who met the inclusion criteria
      were randomized equally to 1 of the treatment groups with iPTH values at screening (&lt; 500
      pg/mL or ≥ 500 pg/mL) as a dynamic allocation factor. Study drugs were administered 3 times
      weekly (every other day) from the venous end of the hemodialysis circuit just before
      completion of the dialysis session. The initial doses were continued for 2 weeks, followed by
      dose adjustments (increase, maintenance, decrease, suspension, or resumption) by 1 µg or 2 µg
      units for the paricalcitol groups and by 2.5 µg units for the maxacalcitol group based on
      iPTH, calcium (adjusted), and phosphorus values every 2 weeks.

      Subjects in the paricalcitol groups were to be suspended from treatment if their iPTH value
      decreased to &lt; 60 pg/mL in accordance with the guidelines proposed by the Japanese Society of
      Dialysis Therapy for the treatment of secondary hyperparathyroidism in chronic dialysis
      patients (control goal value of 60-180 pg/mL for iPTH). The dose adjustment criteria based on
      iPTH values for the maxacalcitol group were set according to the prescribing information for
      maxacalcitol (suspended when iPTH decreased to ≤ 150 pg/mL).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Subjects With ≥ 50% Decrease From Baseline in Intact Parathyroid Hormone (iPTH) Serum Level</measure>
    <time_frame>Baseline to Week 13 (Final Visit)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Intact Parathyroid Hormone (iPTH) Level</measure>
    <time_frame>Baseline to Week 13 (Final Visit)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With Intact Parathyroid Hormone (iPTH) ≤ 180 Picograms/Milliliter (pg/mL)</measure>
    <time_frame>Baseline to Week 13 (Final Visit)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With 2 or More Decreases of ≥ 50% From Baseline in Intact Parathyroid Hormone (iPTH) Level</measure>
    <time_frame>Through Week 13</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of 2 Consecutive Decreases of ≥ 50% From Baseline in Intact Parathyroid Hormone (iPTH) Values</measure>
    <time_frame>Through Week 13</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of 2 Consecutive Intact Parathyroid Hormone (iPTH) Values ≤ 180 pg/mL</measure>
    <time_frame>Through Week 13</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">153</enrollment>
  <condition>Chronic Kidney Disease on Hemodialysis</condition>
  <condition>Secondary Hyperparathyroidism</condition>
  <arm_group>
    <arm_group_label>Paricalcitol 2 µg ± 1 µg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Paricalcitol initial dosage 2 micrograms (µg) with incremental adjustment of 1 µg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Paricalcitol 2 µg ± 2 µg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Paricalcitol initial dosage 2 µg with incremental adjustment of 2 µg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Paricalcitol 4 µg ± 1 µg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Paricalcitol initial dosage 4 µg with incremental adjustment of 1 µg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Paricalcitol 4 µg ± 2 µg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Paricalcitol initial dosage 4 µg with incremental adjustment of 2 µg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Maxacalcitol 5 or 10 µg ± 2.5 µg</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Maxacalcitol initial dosage 5 or 10 µg with incremental adjustment of 2.5 µg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Maxacalcitol</intervention_name>
    <description>Study drug was administered 3 times per week (no more frequently than every other day) intravenously immediately before the completion of hemodialysis. The initial dosage was administered for 2 weeks, with subsequent dosage adjustment based on the subject's iPTH, calcium (adjusted), and phosphorus levels every 2 weeks. Total duration of treatment was 12 weeks.</description>
    <arm_group_label>Maxacalcitol 5 or 10 µg ± 2.5 µg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paricalcitol</intervention_name>
    <description>Study drug was administered 3 times per week (no more frequently than every other day) intravenously immediately before the completion of hemodialysis. The initial dosage was administered for 2 weeks, with subsequent dosage adjustment based on the subject's iPTH, calcium (adjusted), and phosphorus levels every 2 weeks. Total duration of treatment was 12 weeks.</description>
    <arm_group_label>Paricalcitol 2 µg ± 1 µg</arm_group_label>
    <arm_group_label>Paricalcitol 2 µg ± 2 µg</arm_group_label>
    <arm_group_label>Paricalcitol 4 µg ± 1 µg</arm_group_label>
    <arm_group_label>Paricalcitol 4 µg ± 2 µg</arm_group_label>
    <other_name>ABT-358</other_name>
    <other_name>Zemplar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed with chronic kidney disease receiving hemodialysis 3 times a week for at
             least 3 months prior to obtaining the informed consent and scheduled to be receiving
             the same hemodialysis during the study period.

          -  Using dialysate with constant concentration of calcium for 4 weeks prior to obtaining
             informed consent and phosphate binder with constant dose regimen for 2 weeks prior to
             obtaining informed consent.

          -  Intact parathyroid hormone level (iPTH) ≥ 300 pg/mL

          -  Calcium (adjusted) 8.4-10.2 milligrams/deciliter (mg/dL)

          -  Phosphorus ≤ 6.5 mg/dL

          -  Age ≥ 20 years

        Exclusion Criteria:

          -  History of allergic reaction or significant sensitivity to vitamin D or vitamin D
             related compounds

          -  Parathyroidectomy or ethanol infusion within past year

          -  Progressive malignancy or clinically significant hepatic diseases, severe
             cerebral/cardiovascular diseases, severe hypertension, or uncontrolled diabetes
             mellitus

          -  Drug or alcohol abuse within past 6 months

          -  Taking calcitonin, maintenance intravenous or oral glucocorticoids, cinacalcet,
             bisphosphonates, selective estrogen-receptor modulator (SERM), vitamin D compounds
             (other than study drug), or other drugs that may affect calcium or bone metabolism
             (other than estrogen or progestin, vitamin K2)

          -  Will need to take chronic dose (≥ 2 consecutive weeks) of cytochrome P450 (CYP3A)
             inhibitors (e.g., clarithromycin, grapefruit products) or inducers (e.g.,
             carbamazepine, rifampicin)

          -  Taking aluminum containing products (2 weeks prior to consent)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ryotaro Matsuzawa</last_name>
    <role>Study Director</role>
    <affiliation>Abbott</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Tokyo</city>
        <state>Metropolis</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aichi</city>
        <state>Prefecture</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chiba</city>
        <state>Prefecture</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fukuoka</city>
        <state>Prefecture</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hokkaido</city>
        <state>Prefecture</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ibaragi</city>
        <state>Prefecture</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kanagawa</city>
        <state>Prefecture</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kumamoto</city>
        <state>Prefecture</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nagano</city>
        <state>Prefecture</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nagasaki</city>
        <state>Prefecture</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Osaka</city>
        <state>Prefecture</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saitama</city>
        <state>Prefecture</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 24, 2008</study_first_submitted>
  <study_first_submitted_qc>April 25, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 28, 2008</study_first_posted>
  <results_first_submitted>March 18, 2010</results_first_submitted>
  <results_first_submitted_qc>March 18, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 2, 2010</results_first_posted>
  <last_update_submitted>January 18, 2012</last_update_submitted>
  <last_update_submitted_qc>January 18, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 20, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>chronic kidney disease</keyword>
  <keyword>secondary hyperparathyroidism</keyword>
  <keyword>hemodialysis</keyword>
  <keyword>paricalcitol</keyword>
  <keyword>maxacalcitol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Hyperparathyroidism</mesh_term>
    <mesh_term>Hyperparathyroidism, Secondary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Calcitriol</mesh_term>
    <mesh_term>Maxacalcitol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Paricalcitol 2 µg ± 1 µg</title>
          <description>Paricalcitol initial dosage 2 µg with incremental adjustment of 1 µg</description>
        </group>
        <group group_id="P2">
          <title>Paricalcitol 2 µg ± 2 µg</title>
          <description>Paricalcitol initial dosage 2 µg with incremental adjustment of 2 µg</description>
        </group>
        <group group_id="P3">
          <title>Paricalcitol 4 µg ± 1 µg</title>
          <description>Paricalcitol initial dosage 4 µg with incremental adjustment of 1 µg</description>
        </group>
        <group group_id="P4">
          <title>Paricalcitol 4 µg ± 2 µg</title>
          <description>Paricalcitol initial dosage 4 µg with incremental adjustment of 2 µg</description>
        </group>
        <group group_id="P5">
          <title>Maxacalcitol 5 or 10 µg ± 2.5 µg</title>
          <description>Maxacalcitol initial dosage 5 or 10 µg with incremental adjustment of 2.5 µg</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="31"/>
                <participants group_id="P3" count="31"/>
                <participants group_id="P4" count="31"/>
                <participants group_id="P5" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="30"/>
                <participants group_id="P3" count="29"/>
                <participants group_id="P4" count="27"/>
                <participants group_id="P5" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Missed Visit</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Paricalcitol 2 µg ± 1 µg</title>
          <description>Paricalcitol initial dosage 2 µg with incremental adjustment of 1 µg</description>
        </group>
        <group group_id="B2">
          <title>Paricalcitol 2 µg ± 2 µg</title>
          <description>Paricalcitol initial dosage 2 µg with incremental adjustment of 2 µg</description>
        </group>
        <group group_id="B3">
          <title>Paricalcitol 4 µg ± 1 µg</title>
          <description>Paricalcitol initial dosage 4 µg with incremental adjustment of 1 µg</description>
        </group>
        <group group_id="B4">
          <title>Paricalcitol 4 µg ± 2 µg</title>
          <description>Paricalcitol initial dosage 4 µg with incremental adjustment of 2 µg</description>
        </group>
        <group group_id="B5">
          <title>Maxacalcitol 5 or 10 µg ± 2.5 µg</title>
          <description>Maxacalcitol initial dosage 5 or 10 µg with incremental adjustment of 2.5 µg</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
            <count group_id="B2" value="31"/>
            <count group_id="B3" value="31"/>
            <count group_id="B4" value="31"/>
            <count group_id="B5" value="30"/>
            <count group_id="B6" value="153"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="19"/>
                    <measurement group_id="B5" value="12"/>
                    <measurement group_id="B6" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="18"/>
                    <measurement group_id="B6" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.1" spread="11.94"/>
                    <measurement group_id="B2" value="60.7" spread="11.80"/>
                    <measurement group_id="B3" value="58.1" spread="12.35"/>
                    <measurement group_id="B4" value="61.5" spread="11.17"/>
                    <measurement group_id="B5" value="64.1" spread="11.98"/>
                    <measurement group_id="B6" value="61.3" spread="11.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B6" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="17"/>
                    <measurement group_id="B5" value="23"/>
                    <measurement group_id="B6" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="31"/>
                    <measurement group_id="B4" value="31"/>
                    <measurement group_id="B5" value="30"/>
                    <measurement group_id="B6" value="153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects With ≥ 50% Decrease From Baseline in Intact Parathyroid Hormone (iPTH) Serum Level</title>
        <time_frame>Baseline to Week 13 (Final Visit)</time_frame>
        <population>The efficacy analysis was performed on the full analysis set (FAS). The FAS included all treated patients, except for 1 subject from the paricalcitol 4 ± 2 µg group who discontinued the study without measurement of iPTH after the first drug injection. Missing data were not imputed.</population>
        <group_list>
          <group group_id="O1">
            <title>Paricalcitol 2 µg ± 1 µg</title>
            <description>Paricalcitol initial dosage 2 µg with incremental adjustment of 1 µg</description>
          </group>
          <group group_id="O2">
            <title>Paricalcitol 2 µg ± 2 µg</title>
            <description>Paricalcitol initial dosage 2 µg with incremental adjustment of 2 µg</description>
          </group>
          <group group_id="O3">
            <title>Paricalcitol 4 µg ± 1 µg</title>
            <description>Paricalcitol initial dosage 4 µg with incremental adjustment of 1 µg</description>
          </group>
          <group group_id="O4">
            <title>Paricalcitol 4 µg ± 2 µg</title>
            <description>Paricalcitol initial dosage 4 µg with incremental adjustment of 2 µg</description>
          </group>
          <group group_id="O5">
            <title>Maxacalcitol 5 or 10 µg ± 2.5 µg</title>
            <description>Maxacalcitol initial dosage 5 or 10 µg with incremental adjustment of 2.5 µg</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With ≥ 50% Decrease From Baseline in Intact Parathyroid Hormone (iPTH) Serum Level</title>
          <population>The efficacy analysis was performed on the full analysis set (FAS). The FAS included all treated patients, except for 1 subject from the paricalcitol 4 ± 2 µg group who discontinued the study without measurement of iPTH after the first drug injection. Missing data were not imputed.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="31"/>
                <count group_id="O4" value="30"/>
                <count group_id="O5" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.3"/>
                    <measurement group_id="O2" value="41.9"/>
                    <measurement group_id="O3" value="38.7"/>
                    <measurement group_id="O4" value="56.7"/>
                    <measurement group_id="O5" value="43.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Subjects With Hypercalcemia</title>
        <description>Hypercalcemia was defined as at least 1 adjusted calcium value &gt; 11.5 mg/dL or at least 2 consecutive adjusted calcium values ≥ 11.0 mg/dL</description>
        <time_frame>Through Week 13</time_frame>
        <population>Safety analysis was performed on the Safety Set, which included all subjects who received at least 1 dose of study drug. Missing data were not imputed.</population>
        <group_list>
          <group group_id="O1">
            <title>Paricalcitol 2 µg ± 1 µg</title>
            <description>Paricalcitol initial dosage 2 µg with incremental adjustment of 1 µg</description>
          </group>
          <group group_id="O2">
            <title>Paricalcitol 2 µg ± 2 µg</title>
            <description>Paricalcitol initial dosage 2 µg with incremental adjustment of 2 µg</description>
          </group>
          <group group_id="O3">
            <title>Paricalcitol 4 µg ± 1 µg</title>
            <description>Paricalcitol initial dosage 4 µg with incremental adjustment of 1 µg</description>
          </group>
          <group group_id="O4">
            <title>Paricalcitol 4 µg ± 2 µg</title>
            <description>Paricalcitol initial dosage 4 µg with incremental adjustment of 2 µg</description>
          </group>
          <group group_id="O5">
            <title>Maxacalcitol 5 or 10 µg ± 2.5 µg</title>
            <description>Maxacalcitol initial dosage 5 or 10 µg with incremental adjustment of 2.5 µg</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Hypercalcemia</title>
          <description>Hypercalcemia was defined as at least 1 adjusted calcium value &gt; 11.5 mg/dL or at least 2 consecutive adjusted calcium values ≥ 11.0 mg/dL</description>
          <population>Safety analysis was performed on the Safety Set, which included all subjects who received at least 1 dose of study drug. Missing data were not imputed.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="31"/>
                <count group_id="O4" value="31"/>
                <count group_id="O5" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.0"/>
                    <measurement group_id="O2" value="48.4"/>
                    <measurement group_id="O3" value="45.2"/>
                    <measurement group_id="O4" value="58.1"/>
                    <measurement group_id="O5" value="30.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Subjects With Hyperphosphatemia</title>
        <description>Hyperphosphatemia was defined as at least 2 consecutive phosphorus values ≥ 7.0 mg/dL</description>
        <time_frame>Through Week 13</time_frame>
        <population>Safety analysis was performed on the Safety Set, which included all subjects who received at least 1 dose of study drug. Missing data were not imputed.</population>
        <group_list>
          <group group_id="O1">
            <title>Paricalcitol 2 µg ± 1 µg</title>
            <description>Paricalcitol initial dosage 2 µg with incremental adjustment of 1 µg</description>
          </group>
          <group group_id="O2">
            <title>Paricalcitol 2 µg ± 2 µg</title>
            <description>Paricalcitol initial dosage 2 µg with incremental adjustment of 2 µg</description>
          </group>
          <group group_id="O3">
            <title>Paricalcitol 4 µg ± 1 µg</title>
            <description>Paricalcitol initial dosage 4 µg with incremental adjustment of 1 µg</description>
          </group>
          <group group_id="O4">
            <title>Paricalcitol 4 µg ± 2 µg</title>
            <description>Paricalcitol initial dosage 4 µg with incremental adjustment of 2 µg</description>
          </group>
          <group group_id="O5">
            <title>Maxacalcitol 5 or 10 µg ± 2.5 µg</title>
            <description>Maxacalcitol initial dosage 5 or 10 µg with incremental adjustment of 2.5 µg</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Hyperphosphatemia</title>
          <description>Hyperphosphatemia was defined as at least 2 consecutive phosphorus values ≥ 7.0 mg/dL</description>
          <population>Safety analysis was performed on the Safety Set, which included all subjects who received at least 1 dose of study drug. Missing data were not imputed.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="31"/>
                <count group_id="O4" value="31"/>
                <count group_id="O5" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.0"/>
                    <measurement group_id="O2" value="9.7"/>
                    <measurement group_id="O3" value="9.7"/>
                    <measurement group_id="O4" value="19.4"/>
                    <measurement group_id="O5" value="13.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Intact Parathyroid Hormone (iPTH) Level</title>
        <time_frame>Baseline to Week 13 (Final Visit)</time_frame>
        <population>The efficacy analysis was performed on the full analysis set (FAS). The FAS included all treated patients, except for 1 subject from the paricalcitol 4 ± 2 µg group who discontinued the study without measurement of iPTH after the first drug injection. Missing data were not imputed.</population>
        <group_list>
          <group group_id="O1">
            <title>Paricalcitol 2 µg ± 1 µg</title>
            <description>Paricalcitol initial dosage 2 µg with incremental adjustment of 1 µg</description>
          </group>
          <group group_id="O2">
            <title>Paricalcitol 2 µg ± 2 µg</title>
            <description>Paricalcitol initial dosage 2 µg with incremental adjustment of 2 µg</description>
          </group>
          <group group_id="O3">
            <title>Paricalcitol 4 µg ± 1 µg</title>
            <description>Paricalcitol initial dosage 4 µg with incremental adjustment of 1 µg</description>
          </group>
          <group group_id="O4">
            <title>Paricalcitol 4 µg ± 2 µg</title>
            <description>Paricalcitol initial dosage 4 µg with incremental adjustment of 2 µg</description>
          </group>
          <group group_id="O5">
            <title>Maxacalcitol 5 or 10 µg ± 2.5 µg</title>
            <description>Maxacalcitol initial dosage 5 or 10 µg with incremental adjustment of 2.5 µg</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Intact Parathyroid Hormone (iPTH) Level</title>
          <population>The efficacy analysis was performed on the full analysis set (FAS). The FAS included all treated patients, except for 1 subject from the paricalcitol 4 ± 2 µg group who discontinued the study without measurement of iPTH after the first drug injection. Missing data were not imputed.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="31"/>
                <count group_id="O4" value="30"/>
                <count group_id="O5" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-233.2" lower_limit="-313.37" upper_limit="-153.03"/>
                    <measurement group_id="O2" value="-260.8" lower_limit="-366.64" upper_limit="-154.90"/>
                    <measurement group_id="O3" value="-178.2" lower_limit="-246.22" upper_limit="-110.10"/>
                    <measurement group_id="O4" value="-211.7" lower_limit="-309.14" upper_limit="-114.33"/>
                    <measurement group_id="O5" value="-236.6" lower_limit="-311.46" upper_limit="-161.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With Intact Parathyroid Hormone (iPTH) ≤ 180 Picograms/Milliliter (pg/mL)</title>
        <time_frame>Baseline to Week 13 (Final Visit)</time_frame>
        <population>The efficacy analysis was performed on the full analysis set (FAS). The FAS included all treated patients, except for 1 subject from the paricalcitol 4 ± 2 µg group who discontinued the study without measurement of iPTH after the first drug injection. Missing data were not imputed.</population>
        <group_list>
          <group group_id="O1">
            <title>Paricalcitol 2 µg ± 1 µg</title>
            <description>Paricalcitol initial dosage 2 µg with incremental adjustment of 1 µg</description>
          </group>
          <group group_id="O2">
            <title>Paricalcitol 2 µg ± 2 µg</title>
            <description>Paricalcitol initial dosage 2 µg with incremental adjustment of 2 µg</description>
          </group>
          <group group_id="O3">
            <title>Paricalcitol 4 µg ± 1 µg</title>
            <description>Paricalcitol initial dosage 4 µg with incremental adjustment of 1 µg</description>
          </group>
          <group group_id="O4">
            <title>Paricalcitol 4 µg ± 2 µg</title>
            <description>Paricalcitol initial dosage 4 µg with incremental adjustment of 2 µg</description>
          </group>
          <group group_id="O5">
            <title>Maxacalcitol 5 or 10 µg ± 2.5 µg</title>
            <description>Maxacalcitol initial dosage 5 or 10 µg with incremental adjustment of 2.5 µg</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Intact Parathyroid Hormone (iPTH) ≤ 180 Picograms/Milliliter (pg/mL)</title>
          <population>The efficacy analysis was performed on the full analysis set (FAS). The FAS included all treated patients, except for 1 subject from the paricalcitol 4 ± 2 µg group who discontinued the study without measurement of iPTH after the first drug injection. Missing data were not imputed.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="31"/>
                <count group_id="O4" value="30"/>
                <count group_id="O5" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.7"/>
                    <measurement group_id="O2" value="32.3"/>
                    <measurement group_id="O3" value="32.3"/>
                    <measurement group_id="O4" value="36.7"/>
                    <measurement group_id="O5" value="33.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With 2 or More Decreases of ≥ 50% From Baseline in Intact Parathyroid Hormone (iPTH) Level</title>
        <time_frame>Through Week 13</time_frame>
        <population>The efficacy analysis was performed on the full analysis set (FAS). The FAS included all treated subjects, except for 1 subject from the paricalcitol 4 ± 2 µg group who discontinued the study without measurement of iPTH after the first drug injection. Missing data were not imputed.</population>
        <group_list>
          <group group_id="O1">
            <title>Paricalcitol 2 µg ± 1 µg</title>
            <description>Paricalcitol initial dosage 2 µg with incremental adjustment of 1 µg</description>
          </group>
          <group group_id="O2">
            <title>Paricalcitol 2 µg ± 2 µg</title>
            <description>Paricalcitol initial dosage 2 µg with incremental adjustment of 2 µg</description>
          </group>
          <group group_id="O3">
            <title>Paricalcitol 4 µg ± 1 µg</title>
            <description>Paricalcitol initial dosage 4 µg with incremental adjustment of 1 µg</description>
          </group>
          <group group_id="O4">
            <title>Paricalcitol 4 µg ± 2 µg</title>
            <description>Paricalcitol initial dosage 4 µg with incremental adjustment of 2 µg</description>
          </group>
          <group group_id="O5">
            <title>Maxacalcitol 5 or 10 µg ± 2.5 µg</title>
            <description>Maxacalcitol initial dosage 5 or 10 µg with incremental adjustment of 2.5 µg</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With 2 or More Decreases of ≥ 50% From Baseline in Intact Parathyroid Hormone (iPTH) Level</title>
          <population>The efficacy analysis was performed on the full analysis set (FAS). The FAS included all treated subjects, except for 1 subject from the paricalcitol 4 ± 2 µg group who discontinued the study without measurement of iPTH after the first drug injection. Missing data were not imputed.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="31"/>
                <count group_id="O4" value="30"/>
                <count group_id="O5" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.0"/>
                    <measurement group_id="O2" value="100"/>
                    <measurement group_id="O3" value="90.3"/>
                    <measurement group_id="O4" value="90.0"/>
                    <measurement group_id="O5" value="93.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of 2 Consecutive Decreases of ≥ 50% From Baseline in Intact Parathyroid Hormone (iPTH) Values</title>
        <time_frame>Through Week 13</time_frame>
        <population>Includes subjects from the Full Analysis Set (FAS) who had 2 consecutive iPTH decreases of ≥ 50% from baseline. Missing data were not imputed.</population>
        <group_list>
          <group group_id="O1">
            <title>Paricalcitol 2 µg ± 1 µg</title>
            <description>Paricalcitol initial dosage 2 µg with incremental adjustment of 1 µg</description>
          </group>
          <group group_id="O2">
            <title>Paricalcitol 2 µg ± 2 µg</title>
            <description>Paricalcitol initial dosage 2 µg with incremental adjustment of 2 µg</description>
          </group>
          <group group_id="O3">
            <title>Paricalcitol 4 µg ± 1 µg</title>
            <description>Paricalcitol initial dosage 4 µg with incremental adjustment of 1 µg</description>
          </group>
          <group group_id="O4">
            <title>Paricalcitol 4 µg ± 2 µg</title>
            <description>Paricalcitol initial dosage 4 µg with incremental adjustment of 2 µg</description>
          </group>
          <group group_id="O5">
            <title>Maxacalcitol 5 or 10 µg ± 2.5 µg</title>
            <description>Maxacalcitol initial dosage 5 or 10 µg with incremental adjustment of 2.5 µg</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of 2 Consecutive Decreases of ≥ 50% From Baseline in Intact Parathyroid Hormone (iPTH) Values</title>
          <population>Includes subjects from the Full Analysis Set (FAS) who had 2 consecutive iPTH decreases of ≥ 50% from baseline. Missing data were not imputed.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="27"/>
                <count group_id="O5" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.8" spread="14.34"/>
                    <measurement group_id="O2" value="27.7" spread="14.60"/>
                    <measurement group_id="O3" value="29.0" spread="15.26"/>
                    <measurement group_id="O4" value="25.2" spread="18.21"/>
                    <measurement group_id="O5" value="10.9" spread="12.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of 2 Consecutive Intact Parathyroid Hormone (iPTH) Values ≤ 180 pg/mL</title>
        <time_frame>Through Week 13</time_frame>
        <population>Includes subjects from the Full Analysis Set (FAS) who had 2 consecutive iPTH values ≤ 180 pg/mL. Missing data were not imputed.</population>
        <group_list>
          <group group_id="O1">
            <title>Paricalcitol 2 µg ± 1 µg</title>
            <description>Paricalcitol initial dosage 2 µg with incremental adjustment of 1 µg</description>
          </group>
          <group group_id="O2">
            <title>Paricalcitol 2 µg ± 2 µg</title>
            <description>Paricalcitol initial dosage 2 µg with incremental adjustment of 2 µg</description>
          </group>
          <group group_id="O3">
            <title>Paricalcitol 4 µg ± 1 µg</title>
            <description>Paricalcitol initial dosage 4 µg with incremental adjustment of 1 µg</description>
          </group>
          <group group_id="O4">
            <title>Paricalcitol 4 µg ± 2 µg</title>
            <description>Paricalcitol initial dosage 4 µg with incremental adjustment of 2 µg</description>
          </group>
          <group group_id="O5">
            <title>Maxacalcitol 5 or 10 µg ± 2.5 µg</title>
            <description>Maxacalcitol initial dosage 5 or 10 µg with incremental adjustment of 2.5 µg</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of 2 Consecutive Intact Parathyroid Hormone (iPTH) Values ≤ 180 pg/mL</title>
          <population>Includes subjects from the Full Analysis Set (FAS) who had 2 consecutive iPTH values ≤ 180 pg/mL. Missing data were not imputed.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="22"/>
                <count group_id="O5" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.0" spread="12.23"/>
                    <measurement group_id="O2" value="26.1" spread="15.36"/>
                    <measurement group_id="O3" value="19.7" spread="13.32"/>
                    <measurement group_id="O4" value="17.2" spread="15.52"/>
                    <measurement group_id="O5" value="3.1" spread="3.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected after the first dose of study drug until 30 days after the last dose of study drug (up to 12 weeks of treatment).</time_frame>
      <desc>The investigator recorded any undesirable medical events (adverse events) during the study period based on medical interview of the subject, information from medical staff, or spontaneous reporting by the subject.</desc>
      <group_list>
        <group group_id="E1">
          <title>Paricalcitol 2 µg ± 1 µg</title>
          <description>Paricalcitol initial dosage 2 µg with incremental adjustment of 1 µg</description>
        </group>
        <group group_id="E2">
          <title>Paricalcitol 2 µg ± 2 µg</title>
          <description>Paricalcitol initial dosage 2 µg with incremental adjustment of 2 µg</description>
        </group>
        <group group_id="E3">
          <title>Paricalcitol 4 µg ± 1 µg</title>
          <description>Paricalcitol initial dosage 4 µg with incremental adjustment of 1 µg</description>
        </group>
        <group group_id="E4">
          <title>Paricalcitol 4 µg ± 2 µg</title>
          <description>Paricalcitol initial dosage 4 µg with incremental adjustment of 2 µg</description>
        </group>
        <group group_id="E5">
          <title>Maxacalcitol 5 or 10 µg ± 2.5 µg</title>
          <description>Maxacalcitol initial dosage 5 or 10 µg with incremental adjustment of 2.5 µg</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (11.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ventricular extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>shunt stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>shunt aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>spinal osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>cerebellar infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>iliac artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>arteriosclerosis obliterans</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (11.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="28" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="29" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>cheilitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>constipation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>dental caries</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>epigastric discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>puncture site haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>hepatic function abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>arthropod sting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>procedural hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>shunt occlusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>wound</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>blood pressure decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>hypercalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>hyperphosphataemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>back pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>myalgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>restless leg syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>upper respiratory tract inflammation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>skin exfoliation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Abbott requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. Abbott requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if Abbott needs to secure patent or proprietary protection.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Different PTH thresholds were applied for suspending study drug: paricalcitol groups &lt;60 pg/mL, maxacalcitol group ≤150 pg/mL. This study was not statistically powered to compare treatments.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Global Medical Services</name_or_title>
      <organization>Abbott Japan Co., Ltd.</organization>
      <phone>800-633-9110</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

